In July 2014 NICE extended this recommendation to patients at first-line, concluding that, without effective new therapies, the prognosis for advanced disease is very poor.[8] Clinical specialists confirmed to NICE that, for patients with BRAF V600 mutation-negative melanoma, dacarbazine was previously the only first-line treatment option available. This evidence concerns the gene BRAF and melanoma.